# SGLT2 Inhibitor Effects on Inflammation and Heart Disease in Obesity Pilot

> **NCT04907214** · PHASE1,PHASE2 · COMPLETED · sponsor: **Vanderbilt University Medical Center** · enrollment: 29 (actual)

## Conditions studied

- Obesity
- Pre-diabetes

## Interventions

- **DRUG:** Empagliflozin 25 MG

## Key facts

- **NCT ID:** NCT04907214
- **Lead sponsor:** Vanderbilt University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-29
- **Primary completion:** 2023-12-08
- **Final completion:** 2023-12-08
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2023-12-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04907214

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04907214, "SGLT2 Inhibitor Effects on Inflammation and Heart Disease in Obesity Pilot". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04907214. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*